Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maralixibat in Primary Sclerosing Cholangitis
NCT02061540Phase 2Completed
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Mar 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of maralixibat in Primary Sclerosing Cholangitis (PSC), sponsored by Mirum Pharmaceuticals, Inc. Primary endpoints: Treatment-Emergent Adverse Events at 18 weeks and Fasting Serum Bile Acid Level at 14 weeks. Started Mar 2014; status: completed.
02
Drugs
maralixibat
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT02061540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02061540.